ProCE Banner Activity

EINSTEIN CHOICE: Cost Impact Analysis of Continued Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE

Slideset Download
Conference Coverage
At full cost, rivaroxaban increases total healthcare costs but lowers clinical event costs vs aspirin when given as extended anticoagulant therapy for VTE.

Released: December 12, 2017

Expiration: December 11, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Novartis Pharmaceuticals Corporation